Navigation Links
Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome
Date:6/18/2010

BRUSSELS, June 18 /PRNewswire-FirstCall/ -- The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina. Additional data from an open-label extension study showed that the efficacy of rotigotine remained stable over five years of follow up with over a third of patients remaining symptom free during that time and 96% categorized as "very much improved" or "much improved."

"Pain has been reported by up to 60% of RLS patients.  These new data showed that by improving the core symptoms of RLS, rotigotine provided relief from pain and significantly improved patient wellbeing and daily activities impaired due to RLS-related pain. Therefore these data may be relevant for RLS patients with painful symptoms that are not currently being treated effectively," said Professor Ralf Kohnen, University of Erlangen- Nurembourg, Germany.

In the 6-month, double-blind study, 458 patients with moderate to severe RLS were randomised to receive either placebo or rotigotine (1,2,3 mg/24hrs) by transdermal administration.  Patient impairment of daily activities due to pain was assessed using Item 8 of the Quality of Life Questionnaire for RLS patients (QoL-RLS; additional exploratory endpoint). At baseline, 456 patients (99.6%) were assessed and 433 patients (94.5%) were assessed at the end of the maintenance period.

At each visit, patients were asked to what degree pain in their arms or legs impaired their wellbeing or n
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
2. Phosphagenics Announces Completion of Transdermal Patch Prototypes
3. Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
4. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
5. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
6. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
7. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
8. AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System)
9. Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation
10. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
11. Researchers show applied electric field can significantly improve hydrogen storage properties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... for venture capital funds, investment firms and animal health companies to hear from ... raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... Pharmaceutical Holding Company Limited (Biohaven), announced today that ... of BHV-0223, a glutamate modulating agent. Biohaven filed ... recently obtained clearance from the U.S. Food and ... Portage holds 54% equity interest in Biohaven, a ...
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... 19, 2010 Amsterdam Molecular,Therapeutics (EuroNext Amsterdam: AMT), a leader ... update in compliance with,the EU transparency directive. This report summarizes material ... , Q1 2010 Highlights, - ... Dossier validated by EMA on January 20, 2010, ...
... MOUNTAIN VIEW, Calif. , May 19 ... Schall , Ph.D., the Company,s President and Chief Executive ... Entrepreneur Of The Year® 2010 Award in Northern ... awards program recognizes entrepreneurs who demonstrate extraordinary success in ...
... , May 19 Hothead Technologies, Inc. ... the Sivix key computing fob and associated sensor monitoring ... These solutions are based upon the H.O.T.™ System, a ... the helmet of an athlete, firefighter, soldier, or other ...
Cached Biology Technology:AMT Provides Business Update for the First Quarter 2010 2AMT Provides Business Update for the First Quarter 2010 3ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 2ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 3ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 4Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 2Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 3
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... de 2015 La 10 th International Conference ... de BGI del 22 al 25 de octubre de 2015 en ... año, la conferencia celebra su décimo aniversario. Desde su inauguración ... de las reuniones anuales más influyentes del mundo en el ... dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... The 2010 Annual Meeting & OTO EXPO of the ... (AAO-HNSF), the largest meeting of ear, nose, and throat doctors ... MA. , Featuring more than 305 scientific research sessions, ... the annual meeting is a unique opportunity for journalists from ...
... paper published this week in the Proceedings of ... ecologist Dr. Emma Rosi-Marshall and colleagues report that streams ... that originate from adjacent genetically modified crops. The protein ... and plant parts are washed into stream channels. ...
... has received a $15 million grant from the National ... Research Excellence, or INBRE, program. The grant is centered ... the Department of Biological Science in the LSU College ... to strengthen the biomedical research infrastructure and work force ...
Cached Biology News:2010 AAO-HNSF new research highlights: Tuesday, Sept. 28, 2010 22010 AAO-HNSF new research highlights: Tuesday, Sept. 28, 2010 32010 AAO-HNSF new research highlights: Tuesday, Sept. 28, 2010 42010 AAO-HNSF new research highlights: Tuesday, Sept. 28, 2010 5Insecticides from genetically modified corn present in adjacent streams 2LSU receives $15 million grant from NIH to build biomedical research pipeline for Louisiana 2
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
...
...
... Quansys Biosciences Q-Plex Array is a new ... human, mouse, and rat research. The Q-Plex ... ELISA-based test where 4 distinct capture antibodies ... a 96-well plate in a defined array. ...
Biology Products: